Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21764574 | 0.95 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL21764804 | 0.95 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL21764814 | 0.93 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL21764586 | 0.93 | LPAR3 (0.59) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL1194563 | 0.92 | LPAR3 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL17686773 | 0.90 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 | |
| SCHEMBL9463219 | 0.90 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 | |
| SCHEMBL28954648 | 0.90 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 | |
| SCHEMBL393907 | 0.90 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 | |
| SCHEMBL29085821 | 0.90 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR INC. (US) | 2026-05-21 | — | — | US | claimed |
| WO-2023250347-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM, AND FOULING FROM WATER SYSTEMS AND SURFACES | AEQUOR, INC. (US) | 2023-12-28 | — | — | WO | claimed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | claimed |
| CN-115928234-A | Flame-retardant preparation, preparation method and application thereof in preparation of flame-retardant fibers by stock solution coloring | 宇虹颜料股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20220322671-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR, INC. (US) | 2022-10-13 | — | — | US | claimed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2021003419-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR, INC. (US) | 2021-01-07 | — | — | WO | claimed |
| US-20030055240-A1 | HPV specific oligonucleotides | IDERA PHARMACEUTICALS, INC | 2003-03-20 | — | — | US | claimed |
| US-6509149-B2 | Nuclelotide sequences for use in the diagnosis and treatment of human papilloma virus | HYBRIDON, INC. | 2003-01-21 | — | — | US | claimed |
| US-6458940-B2 | HPV-specific oligonucleotides | HYBRIDON, INC. | 2002-10-01 | — | — | US | claimed |
| US-20020068820-A1 | HPV-SPECIFIC OLIGONUCLEOTIDES | IDERA PHARMACEUTICALS, INC | 2002-06-06 | — | — | US | claimed |
| US-20010010899-A1 | HPV-SPECIFIC OLIGONUCLEOTIDES | IDERA PHARMACEUTICALS, INC | 2001-08-02 | — | — | US | claimed |
| EP-0832214-B1 | OLIGONUCLEOTIDES SPECIFIC FOR HUMAN PAPILLOMAVIRUS | HYBRIDON INC (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0832214-A2 | OLIGONUCLEOTIDES SPECIFIC FOR HUMAN PAPILLOMAVIRUS | HYBRIDON, Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039501-A2 | OLIGONUCLEOTIDES SPECIFIC FOR HUMAN PAPILLOMAVIRUS | HYBRIDON INC. (US) | 1996-12-12 | — | — | WO | claimed |
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4682205-A1 | CURED PRODUCT, CURED PRODUCT-CONTAINING CARBON MATERIAL, NEGATIVE ELECTRODE, AND NONAQUEOUS SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| EP-0433446-A1 | HERBICIDAL ORGANO-PHOSPHORUS COMPOUNDS. | TEIJIN LTD (JP) | 1991-06-26 | — | — | EP | disclosed |
| WO-1989012057-A1 | HERBICIDAL ORGANO-PHOSPHORUS COMPOUNDS | TEIJIN LIMITED (JP) | 1989-12-14 | — | — | WO | disclosed |
| US-4838923-A | FOR NARROW-LEAVED WEEDS | TEIJIN LIMITED (JP) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | CYP3A4 1048/4885LPAR3 1324/4885LPAR1 1238/4885 |
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | GRHPR, HAO2, CBR1 | CYP3A4 314/4885LPAR3 208/4885LPAR1 199/4885 |
| US-20220322671-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | PFAS, ERG28, DDT | CYP3A4 1030/4885LPAR3 2162/4885LPAR1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.